Impact of diabetes mellitus on the early-phase arterial healing after drug-eluting stent implantation

Table 5 Logistic regression analysis for minimum NIC of grade 0 (Uncoverage)

	Univariate			Multivariate
	OR	95% CI	p value	OR	95% CI	p value
Male	1.39	0.64–2.84	0.48
Age (1 year increase)	1.00	0.98–1.03	0.98
BMI (1 kg/m² increase)	1.03	0.96–1.09	0.44
Hypertension	0.83	0.42–1.63	0.60
Dyslipidemia	1.39	0.73–2.65	0.35
DM	1.88	1.14–3.10	0.016	2.14	1.19–3.86	0.011
Aspirin*	0.33	0.02–5.32	0.44
Clopidogrel*	0.96	0.59–1.58	0.90
Prasugrel*	1.43	0.86–2.36	0.19
Ticlopidine*	0.22	0.03–1.73	0.20
Statin*	1.55	0.86–2.78	0.16
Follow-up duration	0.995	0.986–1.004	0.31
ACS	0.89	0.53–1.50	0.70
Pre-dilatation balloon maximum diameter (1 mm increase)	1.11	0.75–1.66	0.60
Pre-dilatation balloon maximum inflation pressure (1 atm increase)	1.04	0.97–1.12	0.26
Maximum stent diameter (1 mm increase)	1.24	0.69–2.21	0.48
Minimum stent diameter (1 mm increase)	0.90	0.51–1.60	0.72
Stent implantation pressure (1 atm increase)	0.97	0.91–1.04	0.43
Post-dilatation balloon maximum diameter (1 mm increase)	0.51	0.32–0.83	0.006	0.51	0.31–0.86	0.011
Post-dilatation balloon maximum inflation pressure (1 mm increase)	0.93	0.87–0.990	0.048	0.93	0.86–1.001	0.052
At the time of PCI
Total cholesterol (1 mg/dL increase)	0.995	0.989–1.002	0.18
Triglyceride (1 mg/dL increase)	1.000	0.998–1.003	0.68
HDL-cholesterol (1 mg/dL increase)	0.995	0.976–1.014	0.60
LDL-cholesterol (1 mg/dL increase)	0.994	0/987-1.002	0.15
At the time of CAS evaluation
Total cholesterol (1 mg/dL increase)	0.997	0.990–1.005	0.47
Triglyceride (1 mg/dL increase)	1.001	0.999–1.003	0.50
HDL-cholesterol (1 mg/dL increase)	0.992	0.975–1.010	0.38
LDL-cholesterol (1 mg/dL increase)	0.997	0.987–1.007	0.56

* Medication at the time of coronary angioscopic evaluation. ACS acute coronary syndrome, BMI body mass index, CAS coronary angioscopy, DM diabetes mellitus, HDL high-density lipoprotein, LDL low-density lipoprotein, PCI percutaneous coronary intervention

ISSN: 1475-2840